Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for up to 5 Oligometastases: Preliminary Results of the SABR-5 Trial

被引：0
|
作者：
Olson, R. A. [1 ,2 ]
Jiang, W. [1 ,2 ]
Liu, M. C. [1 ,3 ]
Bergman, A. [3 ]
Schellenberg, D. [1 ,4 ]
Mou, B. [1 ,5 ]
Alexander, A. S. [1 ,6 ]
Carolan, H. [1 ,3 ]
Hsu, F. [1 ,7 ]
Miller, S. [1 ,2 ]
Atrchian, S. [8 ]
Chan, E. K. [1 ,3 ]
Ho, C. [1 ,9 ]
Mohamed, I. G. [1 ,5 ]
Lin, A. [1 ,5 ]
Berrang, T. [1 ,6 ]
Bang, A. [1 ,3 ]
Chng, N. [2 ]
Matthews, Q. [2 ]
Huang, V. [4 ]
Mestrovic, T. [6 ]
Hyde, D.
Lund, C. R. [1 ,4 ]
Pai, H. H. [1 ,6 ]
Valev, B. [1 ,6 ]
Lefresne, S. [10 ,11 ]
Tyldesley, S. [1 ,3 ]
机构：
[1] Univ British Columbia, Vancouver, BC, Canada
[2] BC Canc Prince George, Prince George, BC, Canada
[3] BC Canc Vancouver, Vancouver, BC, Canada
[4] BC Canc Surrey, Surrey, BC, Canada
[5] BC Canc Kelowna, Kelowna, BC, Canada
[6] BC Canc Victoria, Victoria, BC, Canada
[7] BC Canc Abbotsford, Abbotsford, BC, Canada
[8] BC Canc Agcy, Radiat Oncol, Kelowna, BC, Canada
[9] BC Canc Fraser Valley, Surrey, BC, Canada
[10] BC Canc Agcy, Vancouver, BC, Canada
[11] Univ British Columbia, Dept Surg, Div Radiat Oncol, Vancouver, BC, Canada
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [31] Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
    David A Palma
    Cornelis J A Haasbeek
    George B Rodrigues
    Max Dahele
    Michael Lock
    Brian Yaremko
    Robert Olson
    Mitchell Liu
    Jason Panarotto
    GwendolynHMJ Griffioen
    Stewart Gaede
    Ben Slotman
    Suresh Senan
    BMC Cancer, 12
  • [32] Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients.
    Khan, Saad A.
    Gerber, David E.
    Zhu, Hong
    Hughes, Randall S.
    Mannala, Samantha
    Rashdan, Sawsan
    Dowell, Jonathan
    Westover, Kenneth D.
    Saltarski, Jessica
    Harrah, Kasia
    Priddy, Laurin
    Choy, Hak
    Timmerman, Robert D.
    Brekken, Rolf A.
    Sorrelle, Noah
    Iyengar, Puneeth
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
    Palma, David A.
    Haasbeek, Cornelis J. A.
    Rodrigues, George B.
    Dahele, Max
    Lock, Michael
    Yaremko, Brian
    Olson, Robert
    Liu, Mitchell
    Panarotto, Jason
    Griffioen, Gwendolyn H. M. J.
    Gaede, Stewart
    Slotman, Ben
    Senan, Suresh
    BMC CANCER, 2012, 12
  • [34] Stereotactic ablative radiotherapy for oligometastatic cancers: Efficacy and toxicity results from the randomized SABR-COMET Trial
    Senan, S.
    Olson, R.
    Harrow, S.
    Gaede, S.
    Louie, A.
    Haasbeek, C.
    Mulroy, L.
    Lock, M.
    Rodrigues, G.
    Yaremko, B.
    Schellenberg, D.
    Ahmad, B.
    Griffioen, G.
    Senthi, S.
    Liu, M.
    Moore, K.
    Currie, S.
    Bauman, G.
    Warner, A.
    Palma, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [35] Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis from the Population-Based Phase II SABR-5 Trial
    Baker, S.
    Mou, B.
    Jiang, W.
    Liu, M. C.
    Bergman, A.
    Schellenberg, D.
    Alexander, A. S.
    Carolan, H.
    Atrchian, S.
    Berrang, T.
    Bang, A.
    Chng, N.
    Matthews, Q.
    Tyldesley, S. K.
    Olson, R. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S31 - S32
  • [36] TOLERABILITY OF STEREOTACTIC ABLATIVE BODY RADIOTHERAPY (SABR) FOR PRIMARY RENAL CELL CARCINOMA: PRELIMINARY ANALYSIS OF THE FASTRACK CLINICAL TRIAL
    Siva, S.
    Jackson, P.
    Brook, N.
    Grills, R.
    Moon, D.
    Lawrentschuk, N.
    Goad, J.
    Kron, T.
    Gill, S.
    Chander, S.
    Tai, K.
    Shaw, M.
    Pham, D.
    Foroudi, F.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 26 - 27
  • [37] Stereotactic Ablative Body Radiotherapy (SABR) for Oligoprogressive ER-Positive Breast Cancer (AVATAR): A Phase II Prospective Multicenter Trial
    David, S. P.
    Siva, S.
    Bressel, M.
    Tan, J.
    Hanna, G. G.
    Alomran, R. K.
    Yip, E.
    Morton, C.
    Edmonds, M.
    White, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (04): : E6 - E6
  • [38] Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
    David, Steven
    Tan, Jennifer
    Savas, Peter
    Bressel, Mathias
    Kelly, Dianne
    Foroudi, Farshad
    Loi, Sherene
    Siva, Shankar
    BREAST, 2020, 49 : 55 - 62
  • [39] Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Randomized Trial
    Palma, D. A.
    Olson, R. A.
    Harrow, S.
    Gaede, S.
    Louie, A. V.
    Haasbeek, C.
    Mulroy, L.
    Lock, M. I.
    Rodrigues, G.
    Yaremko, B. P.
    Schellenberg, D.
    Ahmad, B.
    Senthi, S.
    Swaminath, A.
    Kopek, N.
    Liu, M. C.
    Moore, K.
    Currie, S.
    Schlijper, R. C. J.
    Bauman, G. S.
    Laba, J. M.
    Qu, M.
    Warner, A.
    Senan, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S88 - S89
  • [40] Validation of the Prognostic Utility of ESTRO/ EORTC Oligometastatic Disease Classification: A Secondary Analysis From the PopulationBased Phase II SABR-5 Trial
    Baker, S.
    Mou, B.
    Jiang, W.
    Liu, M.
    Bergman, A. M.
    Schellenber, D.
    Alexander, A. S.
    Carolan, H.
    Atrchian, S.
    Berrang, T.
    Bang, A.
    Chng, N.
    Matthews, Q.
    Tyldesley, S.
    Olson, R. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (05): : 849 - 855
12345